The fair market value of the Celgene stock was $34,569.60 on 11/21/19. The cost basis was $4117.85.
After Bristol Myers Squibb acquired Celgene, the fair market value of the Bristol Myers Squibb stock was $18,220.80 on 11/21/19. The cost basis was $1,7880.
I received $16,000 in cash as a result of the merger.
How do I compute my tax liability?